Clinical trials of atezolizumab - TrialResults-center.org

Trial	Studied trt	Control trt	patients	tags	ROB	Trial result	death (overall survival)
Group by... in first in second in third	Synopsis Comparison Treatments Patients Characteristics Method Risk of bias References None Tools Indexation					Global trial result Main results All results All result tag NCT results	Numeric bar chart forest plot medians
lung cancer (metastatic)
IMpower150 (WT), 2018 NCT	atezolizumab + bevacizumab	bevacizumab (on top platinum-based CT)	1L	1st line nonsquamous NSCLC	Risk of bias	suggesting
IMpower150 (Teff), 2018 NCT	atezolizumab + bevacizumab	bevacizumab (on top platinum-based CT)	1L, Teff	1st line nonsquamous NSCLC	Risk of bias	suggesting
POPLAR Phase 2 atezolizumab, 2016 NCT	atezolizumab	docetaxel	2L	2nd+ line platinum failure	Risk of bias	negative
OAK, 2016 NCT	atezolizumab	docetaxel	2L	2nd+ line platinum failure	Risk of bias	suggesting
urothelial carcinoma (advanced)
IMvigor211 (IC2/3) NCT	atezolizumab	chemotherapy	2nd line, IC2/3	2nd line	Risk of bias	suggesting
IMVIGOR-130 (monotherapy) NCT	atezolizumab	control	first line	1st line	Risk of bias	remark
IMvigor210 single-arm NCT	atezolizumab	nil	1st and 2nd line	1st line 2nd line	Exploratory	-

Atezolizumab immune checkpoint inhibition systematic review meta-analysis network meta-analysis